| 1183 |
TB Control Program SWOT Analysis |
Pending Review |
08/04/2022 |
| 1100 |
DR-TB Service Referral Linkages Scenario 5: DR-TB Patient Referred for Treatment from the Private Sector with Treatment Initiated in the Private Sector |
Pending Review |
08/04/2022 |
| 1119 |
Precautions to Ensure Reliability of a Test for Diagnosis of DR-TB |
Pending Review |
08/04/2022 |
| 1095 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Treatment Extension |
Pending Review |
08/04/2022 |
| 1096 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Eligibility Criteria |
Pending Review |
08/04/2022 |
| 1097 |
Requirements from Institutions for the Establishment of Nodal DR-TB Centre |
Pending Review |
08/04/2022 |
| 1098 |
DR-TB Services Referral Linkage Scenario 1: Patient Notified from the Private Sector |
Pending Review |
08/04/2022 |
| 1099 |
DR-TB Service Referral Linkages Scenario 3: DR-TB Patient Referred for Treatment from the Private Sector with Bacteriological Confirmation in the Private Sector |
Pending Review |
08/04/2022 |
| 1086 |
Universal Access to Quality TB Care |
Pending Review |
08/04/2022 |
| 1087 |
End TB Strategy Approach |
Pending Review |
08/04/2022 |
| 1085 |
Patient Provider Support Agency [PPSA]: A Multipronged Approach to Engage the Private Sector |
Pending Review |
08/04/2022 |
| 1081 |
Functions of District National Health Mission |
Pending Review |
08/04/2022 |
| 1082 |
District TB Centre and its Functions |
Pending Review |
08/04/2022 |
| 1083 |
Roles of Accredited Social Health Activist [ASHA] for TB Service Delivery at ABHWCs |
Pending Review |
08/04/2022 |
| 1079 |
Importance of Properly Identifying Presumptive TB Cases |
Pending Review |
08/04/2022 |
| 1080 |
Aims and Objectives of Screening for Active TB |
Pending Review |
08/04/2022 |
| 58 |
Presumptive TB |
Live |
08/04/2022 |
| 1077 |
Baseline Second-line Drug-susceptibility Testing |
Pending Review |
08/04/2022 |
| 1063 |
Pre-treatment Counselling of DR-TB Patients |
Pending Review |
07/04/2022 |
| 1069 |
Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Pre-treatment Evaluation [PTE] |
Pending Review |
07/04/2022 |
| 1059 |
Newer Anti-TB Drugs |
Pending Review |
07/04/2022 |
| 1060 |
Newer Anti-TB Drugs: Bedaquiline [Bdq] |
Pending Review |
07/04/2022 |
| 1061 |
Newer Anti-TB Drugs: Delamanid [Dlm] |
Pending Review |
07/04/2022 |
| 1057 |
TB Preventive Treatment [TPT]: Follow-up Monitoring for Contacts of DR-TB Index Patients |
Pending Review |
07/04/2022 |
| 1058 |
TB Preventive Treatment [TPT]: Treatment Adherence for Contacts of DR-TB Index Patients |
Pending Review |
07/04/2022 |
| 274 |
Counselling |
Live |
07/04/2022 |
| 1025 |
Delamanid [Dlm] Drug Dosages and Duration |
Pending Review |
07/04/2022 |
| 995 |
Management of DR-TB ADR: Suicidal Ideation |
Pending Review |
07/04/2022 |
| 996 |
Management of DR-TB ADR: Seizures |
Pending Review |
07/04/2022 |
| 997 |
Management of DR-TB ADR: Nephrotoxicity [Renal Toxicity] |
Pending Review |
07/04/2022 |
